Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Palvella Therapeutics Inc (PVLA)

Palvella Therapeutics Inc (PVLA)
24.31 +0.38 (+1.59%) 15:59 ET [NASDAQ]
23.86 x 200 24.45 x 200
Realtime by (Cboe BZX)
23.86 x 200 24.45 x 200
Realtime - - (-) -
Quote Overview for Wed, Apr 16th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
23.14
Day High
24.73
Open 23.76
Previous Close 23.93 23.93
Volume 82,319 82,319
Avg Vol 97,639 97,639
Stochastic %K 57.34% 57.34%
Weighted Alpha +14.22 +14.22
5-Day Change +2.66 (+12.20%) +2.66 (+12.20%)
52-Week Range 6.20 - 29.27 6.20 - 29.27
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 263,685
  • Shares Outstanding, K 11,019
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,430 K
  • EBIT $ -14 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.38

Options Overview Details

View History
  • Implied Volatility 97.84% ( -12.41%)
  • Historical Volatility 112.02%
  • IV Percentile 29%
  • IV Rank 17.08%
  • IV High 150.04% on 02/05/25
  • IV Low 87.09% on 04/02/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 2
  • Put/Call OI Ratio 0.96
  • Today's Open Interest 153
  • Open Int (30-Day) 153

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -3.39
  • Number of Estimates 2
  • High Estimate -3.23
  • Low Estimate -3.56
  • Prior Year -3.95
  • Growth Rate Est. (year over year) +14.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.23 +34.21%
on 04/09/25
Period Open: 27.47
29.12 -16.00%
on 03/25/25
-3.00 (-10.94%)
since 03/14/25
3-Month
12.10 +102.15%
on 01/24/25
Period Open: 13.22
29.27 -16.43%
on 03/13/25
+11.24 (+85.03%)
since 01/16/25
52-Week
6.20 +294.52%
on 07/12/24
Period Open: 13.12
29.27 -16.43%
on 03/13/25
+11.34 (+86.44%)
since 04/16/24

Most Recent Stories

More News
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg...

PVLA : 24.31 (+1.59%)
Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

PVLA : 24.31 (+1.59%)
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

PVLA : 24.31 (+1.59%)
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

PVLA : 24.31 (+1.59%)
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

PVLA : 24.31 (+1.59%)
Palvella - Undiscovered Biotechnology Stock

Summary Palvella Therapeutics (PVLA) has shown significant price appreciation, gaining 90% since a Trend Seeker buy signal on 2/5, and 105.81% over the last year. The company focuses on developing therapies...

PVLA : 24.31 (+1.59%)
Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

PVLA : 24.31 (+1.59%)
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORINâ„¢ 3.9% Rapamycin Anhydrous Gel (QTORINâ„¢ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

PVLA : 24.31 (+1.59%)
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORINâ„¢ 3.9% Rapamycin Anhydrous Gel (QTORINâ„¢ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies

PVLA : 24.31 (+1.59%)
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORINâ„¢ 3.9% Rapamycin Anhydrous Gel (QTORINâ„¢ rapamycin) for the Treatment of Cutaneous Venous Malformations

PVLA : 24.31 (+1.59%)

Business Summary

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

See More

Key Turning Points

3rd Resistance Point 26.83
2nd Resistance Point 26.12
1st Resistance Point 25.02
Last Price 24.31
1st Support Level 23.21
2nd Support Level 22.50
3rd Support Level 21.40

See More

52-Week High 29.27
Last Price 24.31
Fibonacci 61.8% 20.46
Fibonacci 50% 17.74
Fibonacci 38.2% 15.01
52-Week Low 6.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro